000866622 001__ 866622
000866622 005__ 20210130003544.0
000866622 0247_ $$2Handle$$a2128/23520
000866622 037__ $$aFZJ-2019-05701
000866622 041__ $$aEnglish
000866622 1001_ $$0P:(DE-Juel1)132740$$aHumpert, Swen$$b0$$eCorresponding author$$ufzj
000866622 1112_ $$aThe 23rd International Symposium on Radiopharmaceutical Sciences$$cBeijing$$d2019-05-26 - 2019-05-31$$wChina
000866622 245__ $$aPreparation of [18F]fluoroalkenyliodonium salts and their application for radiolabeling by cross‐coupling reactions
000866622 260__ $$c2019
000866622 3367_ $$033$$2EndNote$$aConference Paper
000866622 3367_ $$2DataCite$$aOther
000866622 3367_ $$2BibTeX$$aINPROCEEDINGS
000866622 3367_ $$2DRIVER$$aconferenceObject
000866622 3367_ $$2ORCID$$aLECTURE_SPEECH
000866622 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1575374867_14689$$xAfter Call
000866622 520__ $$aObjective(Fluoroalkenyl)(aryl)iodonium salts are valuable building blocks for Pd‐catalyzed cross‐coupling reactions [1]. These prosthetic groups are easily available via nucleophilic addition of fluoride to the respective (alkynyl)(aryl)iodonium salts under exceptionally mild conditions [2]. Herein we report the preparation of 18F‐labeled (2‐fluorohexen‐1‐yl)(aryl)iodonium salts ([18F]FHexI+X–) and their application in various Pd‐catalyzed cross‐coupling reactions. Finally, [18F]FHexI+OTs– was used for the site selective labeling of clinically relevant compounds and peptides.Methods(Alkynyl)(aryl)iodonium salts were radiolabeled using [18F]fluoride in aqueous media in the presence of different bases and K2.2.2. The reaction conditions were optimized with respect to different parameters including reaction temperature, time, solvent, precursor amount and counter ion. After isolation, [18F]FHexI+OTs– was applied in Pd‐catalyzed cross‐couplings with different model substrates. Additionally, radiofluorinated amino acid derivatives as well as a PSMA ligand potentially suitable for the detection of prostate carcinoma lesions were prepared starting from [18F]FHexI+OTs–.ResultsUnder optimized conditions (KHCO3, K2.2.2, 67% aq. DMSO, 75°C) [18F]FHexI+X– salts were prepared in RCYs of about 60% (HPLC) within 10 min. Remarkably, time consuming azeotropic drying was not necessary. Radiolabeling of the phenylethynyl substituted precursors also furnished the respective 18F‐labeled iodonium salts although in lower RCYs of 20% to 30% (HPLC). The respective counter ion (OTs–, OMs–, BF4–, TFA–) did not have a significant influence on RCYs. [18F]FHexI+OTs– was purified by HPLC followed by solvent exchange and thereafter used for subsequent cross‐coupling reactions. Sonogashira, Stille, and Suzuki reactions afforded the respective radiolabeled products as pure Z‐isomers in RCYs of 61% to 74% (HPLC) within 3 to 10 min at ambient temperature. In the case of the Heck cross‐coupling the corresponding 18F‐fluorinated diene was prepared in RCY of 27 ± 2% as a mixture of E/Z isomers.In particular, the one‐pot Sonogashira cross‐coupling reaction turned out to be very fast and robust under very mild conditions. Therefore, this reaction was selected to demonstrate the applicability of [18F]FHexI+ for the labeling of biomolecules. Nine ethynyl‐substituted amino acid derivatives were conjugated with [18F]FHexI+OTs– using the Sonogashira reaction affording the respective radiolabeled enynes in RCYs of 38% to 88% (HPLC). Furthermore, a novel 18F‐labeled PSMA ligand was prepared in an isolated RCY of 40% in two steps within 35 min. Conjugation of [18F]FHexI+OTs– to a suitably modified model dipeptide (H‐Arg‐Pra‐OBn) afforded the corresponding conjugate in 61% RCY based on isolated [18F]FHexI+OTs– using only 50 nmol peptide precursor.ConclusionThe novel radiolabeled prosthetic group [18F]FHexI+OTs– is easily available in aqueous media obviating any evaporation steps. Thus, [18F]FHexI+OTs– can be used in Pd‐catalyzed cross‐coupling reactions as a fast, high yielding, site specific and versatile procedure for the preparation of clinically relevant PET tracers. [1] Yoshida et al., Tetrahedron 62 (2006) 8636‐8645 [2] Nguyen et al., Tetrahedron 67 (2011) 3434‐34939image
000866622 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000866622 7001_ $$0P:(DE-Juel1)131824$$aHolschbach, Marcus$$b1$$ufzj
000866622 7001_ $$0P:(DE-Juel1)131810$$aBier, Dirk$$b2$$ufzj
000866622 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris$$b3$$ufzj
000866622 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b4$$ufzj
000866622 8564_ $$uhttps://juser.fz-juelich.de/record/866622/files/Abstract%20ISRS%202019%20Humpert.pdf$$yOpenAccess
000866622 8564_ $$uhttps://juser.fz-juelich.de/record/866622/files/Abstract%20ISRS%202019%20Humpert.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000866622 909CO $$ooai:juser.fz-juelich.de:866622$$pdriver$$pVDB$$popen_access$$popenaire
000866622 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132740$$aForschungszentrum Jülich$$b0$$kFZJ
000866622 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131824$$aForschungszentrum Jülich$$b1$$kFZJ
000866622 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131810$$aForschungszentrum Jülich$$b2$$kFZJ
000866622 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)176188$$aForschungszentrum Jülich$$b3$$kFZJ
000866622 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b4$$kFZJ
000866622 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000866622 9141_ $$y2019
000866622 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000866622 920__ $$lyes
000866622 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000866622 980__ $$aconf
000866622 980__ $$aVDB
000866622 980__ $$aUNRESTRICTED
000866622 980__ $$aI:(DE-Juel1)INM-5-20090406
000866622 9801_ $$aFullTexts